Evofem Biosciences, Inc.

Windtree Therapeutics Partners with Evofem to Manufacture FDA-Approved Contraceptive PHEXXI

2 months ago

• Windtree Therapeutics has entered into a License and Supply Agreement with Evofem Biosciences to become the sourcing partner for PHEXXI, a hormone-free contraceptive vaginal gel that generated over $19 million in annual revenue in 2024. • The partnership aims to significantly reduce manufacturing costs for PHEXXI, potentially enabling Evofem to expand into new price-sensitive global markets where non-hormonal contraceptives are in high demand. • This agreement represents the first step in Windtree's recently announced corporate strategy to transform into a revenue-generating biotechnology company while continuing development of its therapeutic pipeline.

Windtree's Istaroxime Shows Promise in Cardiogenic Shock Treatment and Arrhythmia Prevention

5 months ago

• Alexandre Mebazaa presented positive Phase 2b data on istaroxime for early cardiogenic shock at the Cardiovascular Clinical Trials Conference. • Istaroxime is a first-in-class therapy improving cardiac function and blood pressure without increasing heart rate, showing a favorable safety profile. • Windtree has filed a patent application in India for istaroxime, aiming to protect its use in preventing myocardial arrhythmias. • The company is advancing istaroxime towards Phase 3 trials, driven by promising Phase 2 results and the drug's unique mechanism of action.